s0112300
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.400
- ESTROGEN_RESPONSE_LATE+0.400
- CHOLESTEROL_HOMEOSTASIS+0.300
- ESTROGEN_RESPONSE_EARLY+0.300
- FATTY_ACID_METABOLISM+0.300
- KRAS_SIGNALING_DN+0.300
- NOTCH_SIGNALING+0.300
- ADIPOGENESIS+0.200
- MYOGENESIS+0.200
- PEROXISOME+0.200
Top 10 suppressed
- E2F_TARGETS-0.600
- INTERFERON_ALPHA_RESPONSE-0.600
- MYC_TARGETS_V1-0.600
- ALLOGRAFT_REJECTION-0.500
- G2M_CHECKPOINT-0.500
- INTERFERON_GAMMA_RESPONSE-0.500
- MYC_TARGETS_V2-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.500
- DNA_REPAIR-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2208930 | — | — | 0.907 |
| 2 | s0122230 | — | — | 0.891 |
| 3 | BS_AD4JPN9Q | Ganglioglioma | — | 0.869 |
| 4 | s0112264 | — | — | 0.868 |
| 5 | SRR29022834 | — | A | 0.861 |
| 6 | aMVAC.P_003_TURBT_S220 | — | — | 0.859 |
| 7 | TCGA-B6-A0RQ-01A-11R-A115-07 | — | A | 0.853 |
| 8 | TCGA-55-8616-01A-11R-2403-07 | — | cohortA1 | 0.843 |
| 9 | TCGA-E2-A14U-01A-11R-A22K-07 | — | A | 0.838 |
| 10 | ERR2208949 | — | — | 0.837 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.400 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.400 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |